Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells

Molecular Nutrition and Food Research

Volumn 58, Issue 11, 2014, Pages 2133-2145

  Tai, Mi Hsueh ^a   Chen, Po Kong ^a   Chen, Pei Yi ^b   Wu, Ming Jiuan ^c   Ho, Chi Tang ^d   Yen, Jui Hung ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Curcumin; HNF 1 ; Hypercholesterolemia; LDLR; PCSK9

Indexed keywords

CURCUMIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

CELL MEMBRANE; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEPG2 CELL LINE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL; METABOLISM;

CELL MEMBRANE; CHOLESTEROL, LDL; CURCUMIN; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TRANSCRIPTION, GENETIC;

EID: 84922702017     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400366     Document Type: Article

References (68)

1. Keys, A., Taylor, H. L., Blackburn, H., Brozek, J. et al., Mortality and coronary heart disease among men studied for 23 years. Arch. Intern. Med. 1971, 128, 201-214.
2. Beglova, N., Blacklow, S. C., The LDL receptor: how acid pulls the trigger? Trends Biochem. Sci. 2005, 30, 309-317.
3. Goldstein, J. L., Brown, M. S., The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 431-438.
4. Innerarity, T. L., Mahley, R. W., Weisgraber, K. H., Bersot, T. P. et al., Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J. Lipid Res. 1990, 31, 1337-1349.
5. Abifadel, M., Varret, M., Rabes, J. P., Allard, D. et al., Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34, 154-156.
6. Timms, K. M., Wagner, S., Samuels, M. E., Forbey, K. et al., A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 2004, 114, 349-353.
7. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J. et al., The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 2003, 100, 928-933.
8. Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J. et al., NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 2004, 279, 48865-48875.
9. Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z. et al., Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 2007, 282, 18602-18612.
10. Maxwell, K. N., Breslow, J. L., Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA 2004, 101, 7100-7105.
11. Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr., Hobbs, H. H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 2006, 354, 1264-1272.
12. Cameron, J., Holla, O. L., Ranheim, T., Kulseth, M. A. et al., Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 2006, 15, 1551-1558.
13. Akram, O. N., Bernier, A., Petrides, F., Wong, G., et al., Beyond LDL cholesterol, a new role for PCSK9. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1279-1281.
14. Soutar, A. K., Unexpected roles for PCSK9 in lipid metabolism. Curr. Opin. Lipidol. 2011, 22, 192-196.
15. Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N. et al., Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 2003, 100, 12027-12032.
16. Li, H., Dong, B., Park, S. W., Lee, H. S. et al., Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem. 2009, 284, 28885-28895.
17. Dubuc, G., Chamberland, A., Wassef, H., Davignon, J. et al., Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1454-1459.
18. Maxwell, K. N., Soccio, R. E., Duncan, E. M., Sehayek, E. et al., Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 2003, 44, 2109-2119.
19. Jeong, H. J., Lee, H. S., Kim, K. S., Kim, Y. K. et al., Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J. Lipid Res. 2008, 49, 399-409.
20. Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N. et al., Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA 2005, 102, 5374-5379.
21. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. et al., Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 2006, 79, 514-523.
22. Vogel, R. A., PCSK9 inhibition: the next statin? J. Am. Coll. Cardiol. 2012, 59, 2354-2355.
23. Poirier, S., Mayer, G., The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des. Devel. Ther. 2013, 7, 1135-1148.
24. Basnet, P., Skalko-Basnet, N., Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011, 16, 4567-4598.
25. Srivastava, R., Dikshit, M., Srimal, R. C., Dhawan, B. N., Anti-thrombotic effect of curcumin. Thromb. Res. 1985, 40, 413-417.
26. Kim, K. M., Pae, H. O., Zhung, M., Ha, H. Y. et al., Involvement of anti-inflammatory heme oxygenase-1 in the inhibitory effect of curcumin on the expression of pro-inflammatory inducible nitric oxide synthase in RAW264.7 macrophages. Biomed. Pharmacother. 2008, 62, 630-636.
27. Zheng, M., Zhang, Q., Joe, Y., Lee, B. H. et al., Curcumin induces apoptotic cell death of activated human CD4+ T cells via increasing endoplasmic reticulum stress and mitochondrial dysfunction. Int. Immunopharmacol. 2013, 15, 517-523.
28. Zingg, J. M., Hasan, S. T., Cowan, D., Ricciarelli, R. et al., Regulatory effects of curcumin on lipid accumulation in monocytes/macrophages. J. Cell Biochem. 2012, 113, 833-840.
29. Kou, M. C., Chiou, S. Y., Weng, C. Y., Wang, L. et al., Curcuminoids distinctly exhibit antioxidant activities and regulate expression of scavenger receptors and heme oxygenase-1. Mol. Nutr. Food Res. 2013, 57, 1598-1610.
30. Ramirez-Tortosa, M. C., Mesa, M. D., Aguilera, M. C., Quiles, J. L. et al., Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 1999, 147, 371-378.
31. Quiles, J. L., Mesa, M. D., Ramirez-Tortosa, C. L., Aguilera, C. M. et al., Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1225-1231.
32. Soni, K. B., Kuttan, R., Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J. Physiol. Pharmacol. 1992, 36, 273-275.
33. Ramirez-Bosca, A., Soler, A., Carrion, M. A., Diaz-Alperi, J. et al., An hydroalcoholic extract of Curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mech. Ageing Dev. 2000, 119, 41-47.
34. Dou, X., Fan, C., Wo, L., Yan, J. et al., Curcumin up-regulates LDL receptor expression via the sterol regulatory element pathway in HepG2 cells. Planta Med. 2008, 74, 1374-1379.
35. Peschel, D., Koerting, R., Nass, N., Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J. Nutr. Biochem. 2007, 18, 113-119.
36. Kang, Q., Chen, A., Curcumin inhibits SREBP-2 expression in activated hepatic stellate cells in vitro by reducing the activity of specificity protein-1. Endocrinology 2009, 150, 5384-5394.
37. Kang, Q., Chen, A., Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br. J. Pharmacol. 2009, 157, 1354-1367.
38. Meex, S. J., Andreo, U., Sparks, J. D., Fisher, E. A., Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? J. Lipid Res. 2011, 52, 152-158.
39. Harwood, H. J., Jr., Pellarin, L. D., Kinetics of low-density lipoprotein receptor activity in Hep-G2 cells: derivation and validation of a Briggs-Haldane-based kinetic model for evaluating receptor-mediated endocytotic processes in which receptors recycle. Biochem. J. 1997, 323(Pt 3), 649-659.
40. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D. et al., Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47, 936-942.
41. {increment}{increment}Ct Method. Methods 2001, 25, 402-408.
42. Kong, W., Wei, J., Abidi, P., Lin, M. et al., Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10, 1344-1351.
43. Yen, J. H., Weng, C. Y., Li, S., Lo, Y. H. et al., Citrus flavonoid 5-demethylnobiletin suppresses scavenger receptor expression in THP-1 cells and alters lipid homeostasis in HepG2 liver cells. Mol. Nutr. Food Res. 2011, 55, 733-748.
44. Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P. et al., Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008, 201, 266-273.
45. Chen, P. Y., Yen, J. H., Kao, R. H., Chen, J. H., Down-regulation of the oncogene PTTG1 via the KLF6 tumor suppressor during induction of myeloid differentiation. PLoS One 2013, 8, e71282.
46. Chakrabarti, S. K., James, J. C., Mirmira, R. G., Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding. J. Biol. Chem. 2002, 277, 13286-13293.
47. Yu, H. T., Yu, M., Li, C. Y., Zhan, Y. Q. et al., Specific expression and regulation of hepassocin in the liver and down-regulation of the correlation of HNF1alpha with decreased levels of hepassocin in human hepatocellular carcinoma. J. Biol. Chem. 2009, 284, 13335-13347.
48. Seo, K. I., Choi, M. S., Jung, U. J., Kim, H. J. et al., Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol. Nutr. Food Res. 2008, 52, 995-1004.
49. Hasan, S. T., Zingg, J. M., Kwan, P., Noble, T. et al., Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis 2014, 232, 40-51.
50. Vareed, S. K., Kakarala, M., Ruffin, M. T., Crowell, J. A. et al., Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 1411-1417.
51. Hoehle, S. I., Pfeiffer, E., Solyom, A. M., Metzler, M., Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. J. Agric. Food Chem. 2006, 54, 756-764.
52. Pan, M. H., Huang, T. M., Lin, J. K., Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 1999, 27, 486-494.
53. Ireson, C. R., Jones, D. J., Orr, S., Coughtrie, M. W. et al., Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev. 2002, 11, 105-111.
54. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M. et al., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21, 2895-2900.
55. Shoji, M., Nakagawa, K., Watanabe, A., Tsuduki, T. et al., Comparison of the effects of curcumin and curcumin glucuronide in human hepatocellular carcinoma HepG2 cells. Food Chem. 2014, 151, 126-132.
56. Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J. et al., Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008, 48, 646-654.
57. Le May, C., Kourimate, S., Langhi, C., Chetiveaux, M. et al., Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 684-690.
58. Maxwell, K. N., Fisher, E. A., Breslow, J. L., Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA 2005, 102, 2069-2074.
59. Horton, J. D., Cohen, J. C., Hobbs, H. H., Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 2007, 32, 71-77.
60. Zelcer, N., Hong, C., Boyadjian, R., Tontonoz, P., LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325, 100-104.
61. Cariou, B., Le May, C., Costet, P., Clinical aspects of PCSK9. Atherosclerosis 2011, 216, 258-265.
62. Wu, M., Dong, B., Cao, A., Li, H. et al., Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters. Atherosclerosis 2012, 224, 401-410.
63. Dong, B., Wu, M., Li, H., Kraemer, F. B. et al., Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res. 2010, 51, 1486-1495.
64. Shen, G., Xu, C., Hu, R., Jain, M. R. et al., Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol. Cancer Ther. 2006, 5, 39-51.
65. Balstad, T. R., Carlsen, H., Myhrstad, M. C., Kolberg, M. et al., Coffee, broccoli and spices are strong inducers of electrophile response element-dependent transcription in vitro and in vivo-studies in electrophile response element transgenic mice. Mol. Nutr. Food Res. 2011, 55, 185-197.
66. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360, 7-22.
67. Careskey, H. E., Davis, R. A., Alborn, W. E., Troutt, J. S. et al., Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 2008, 49, 394-398.
68. Welder, G., Zineh, I., Pacanowski, M. A., Troutt, J. S. et al., High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J. Lipid Res. 2010, 51, 2714-2721.